{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-110852","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.308518+00:00","generated_at":"2026-05-16T20:14:05.062588+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sagimet reports Q3 2025 net loss $12.9M; advances denifanstat + resmetirom combo trial","bullets":["Net loss for Q3 2025 was $12.9M vs $14.6M YoY; nine-month net loss $41.5M vs $29.4M.","Cash, cash equivalents and marketable securities totaled $125.5M as of Sept 30, 2025.","Phase 1 PK trial of denifanstat plus resmetirom in MASH cirrhosis underway; data expected 1H 2026.","Partner Ascletis completed pre-NDA consultation with China NMPA for denifanstat in acne vulgaris; NDA submission planned.","Marie O'Farrell promoted to CSO and Liz Rozek to Chief Legal & Admin Officer effective Nov 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-110852","json":"https://secwatch.observer/filing/0001104659-25-110852.json","markdown":"https://secwatch.observer/filing/0001104659-25-110852.md","text":"https://secwatch.observer/filing/0001104659-25-110852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/0001104659-25-110852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:14:05.062588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}